NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $105.87 +7.84 (+8.00%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$103.90 -1.98 (-1.87%) As of 09:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$98.08▼$106.4850-Day Range$93.19▼$105.9852-Week Range$49.38▼$107.84Volume878,394 shsAverage Volume520,415 shsMarket Capitalization$6.81 billionP/E RatioN/ADividend YieldN/APrice Target$115.21Consensus RatingModerate Buy Company Overview Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care. Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis. Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 700th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingProtagonist Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.93 to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -58.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -58.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 10.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.15% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 16.81, which indicates bearish sentiment.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 1.60%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.47 News SentimentProtagonist Therapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,707,266.00 in company stock.Percentage Held by Insiders5.19% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 Shares of StockJune 3, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesJune 2, 2026 | insidertrades.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 10 at 1:00 AM | Porter & Company (Ad)Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 30, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 75,000 SharesMay 13, 2026 | insidertrades.comAnalyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging HigherMay 11, 2026 | finance.yahoo.comProtagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsMay 9, 2026 | finance.yahoo.comIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7, 2026 | finance.yahoo.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $87.34 at the start of the year. Since then, PTGX stock has increased by 21.2% and is now trading at $105.87. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its earnings results on Tuesday, May, 5th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 17.76% and a negative net margin of 154.88%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $90 million in an IPO on Wednesday, August 10th 2016. The company issued 7,500,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional shareholders of Protagonist Therapeutics include Janus Henderson Group PLC (4.50%), Bank of America Corp DE (2.01%), Perceptive Advisors LLC (1.91%) and Jennison Associates LLC (1.67%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Harold E Selick, Asif Ali, Bryan Giraudo, William D Waddill and Lewis T Williams. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings5/05/2026Today6/10/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/10/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 PTGX's financial health is in the Green zone, according to TradeSmith. PTGX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$115.21 High Price Target$137.00 Low Price Target$82.00 Potential Upside/Downside+8.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.81) Trailing P/E RatioN/A Forward P/E Ratio36.13 P/E GrowthN/ANet Income-$130.15 million Net Margins-154.88% Pretax Margin-155.78% Return on Equity-17.76% Return on Assets-16.47% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.76 Sales & Book Value Annual Sales$46.02 million Price / Sales147.95 Cash FlowN/A Price / Cash FlowN/A Book Value$9.83 per share Price / Book10.77Miscellaneous Outstanding Shares64,310,000Free Float60,973,000Market Cap$6.81 billion OptionableOptionable Beta1.85 Social Links Missed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PTGX) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
